Viz.ai Expands to the Netherlands with a Focus on Life-Saving Diagnostics
The U.S.-based company brings innovation to global healthcare using cutting-edge AI
Viz.ai, a pioneer in information and communications technology (ICT) focused on life sciences and health, has expanded to the Netherlands. Named a Forbes Top 50 AI company in 2021, the U.S.-based Viz.ai develops software focused on increasing diagnostic speed for various acute and emergent diseases across hospitals and health systems.
A leader in applied artificial intelligence, including machine and deep learning, Viz.ai software helps reduce diagnostic times to mere minutes. For stroke and pulmonary embolisms medical professionals, the technology is helping save lives.
Advancing healthcare with intelligent software
At home in the highly collaborative Dutch life sciences and health ecosystem, Viz.ai is on a mission to improve how healthcare is delivered to the world. Its cutting-edge AI is one of the world’s leading innovations in the field.
Viz.ai intelligent software reduces the time to treatment while improving access to care. The company’s products include Viz LVO, the first-ever computer-aided triage and notification platform. The AI-powered app uses deep learning to communicate time-sensitive information about stroke patients. The platform ensures specialists receive up-to-date, critical information quickly, making it easier for them to intervene and provide treatment. It also coordinates care by connecting frontline health care professionals.
Ground-breaking solutions in life sciences and health
With a proven record of ground-breaking developments in life sciences and health, the Netherlands’ ongoing commitment to innovation attracts companies like Viz.ai to the highly connected and collaborative Dutch ecosystem.
Viz.ai will be able to accelerate its innovation by connecting to the Netherlands’ 4.7-billion-euro medtech market that includes 3,000+ R&D life sciences companies, 26 campuses, 7 University Medical Centers, and 13 universities engaged in Life Sciences research.
In the Netherlands, Viz.ai also benefits from access to a number of regulatory authorities, including the European Medicines Agency (EMA), the U.S. Food & Drug Administration, as well as the Medicines Evaluation Board (MEB). In 2020, Viz LVO became the first AI software to receive approval from the Centers for Medicare & Medicaid Services (CMS) in the United States.
Progress through partnership
The Netherlands Foreign Investment Agency (NFIA) played an essential role in facilitating Viz.ai’s expansion to the country, guiding the company on a smooth transition to the Dutch life sciences & health ecosystem.
Before settling in the Netherlands, Viz.ai looked at other countries, but the benefits, including location, access provided via Amsterdam Airport Schiphol, and an English-speaking population, will make it easy for Viz.ai to attract top talent and grow their business and innovation.
About Viz.ai
Viz.ai, Inc is a leader in applied artificial intelligence in healthcare. Their mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care. Viz.ai, a Forbes AI top 50 company, 2021, is in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Green Oaks, CRV and Threshold Ventures.
Source: Viz.ai
5 April 2023